These results revealed that the better efficacy of Res in the treatment of ihDCTC tumor-bearing mice than Cis might be associated with the fact that Res could effectively inhibit the expression of IL-6-p-STAT3-NF-κB in xenograft tissue. The gene discussed is NFKB1; the disease is neoplasm.